<DOC>
	<DOCNO>NCT00498550</DOCNO>
	<brief_summary>Many individual schizophrenia also suffer marijuana addiction . Clozapine , atypical antipsychotic medication , may prove useful prevent drug relapse schizophrenic individual seek treatment marijuana addiction . The purpose study compare effectiveness clozapine , vs. treatment-as-usual oral antipsychotic reduce marijuana use schizophrenic individual .</brief_summary>
	<brief_title>Treatment Schizophrenia Comorbid Cannabis Use Disorder : Comparing Clozapine Treatment-as-Usual</brief_title>
	<detailed_description>Individuals schizophrenia high risk become addict drug ; 13 42 % schizophrenic addict marijuana . These individual often difficulty adhere substance abuse treatment program , increase chance marijuana relapse . Marijuana use schizophrenic also associate clinical exacerbation , noncompliance antipsychotic medication , poor global functioning , increased rehospitalization rate . While antipsychotic medication often effective control symptom schizophrenia , always effective prevent substance abuse . Clozapine , atypical antipsychotic drug , currently use treat schizophrenia . Preliminary research show clozapine successful reduce drug relapse rate individual schizophrenia , compare antipsychotic medication , include olanzapine risperidone . The purpose study compare effectiveness clozapine compare oral antipsychotic treatment , include combination two antipsychotic , reduce marijuana use schizophrenic individual . This study enroll individual schizophrenia currently take oral antipsychotic clozapine , include take two oral antipsychotic , also addict marijuana . The study begin 1-week assessment phase , participant continue take olanzapine risperidone . Participants undergo physical examination blood drawn laboratory test . Information pertain medical , psychiatric , substance use history also collect . Urine test breathalyzer use screen presence alcohol drug . Following assessment phase , participant randomly assign switch clozapine remain prestudy antipsychotic 12 week . Participants remain prestudy antipsychotic treatment continue receive dose entire study . Participants take clozapine initially receive daily dose 12.5 mg , increase maximum 400 mg per day , tolerate . Study visit take place week . At visit , medication side effect , physical psychological symptom , substance use , treatment service receive , live situation assess . Blood drawn laboratory test . Drug alcohol level monitor three time week urine breathalyzer test . Quality life questionnaire administer month .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>Meets Diagnostic Statical Manual Mental Disorders IV ( DSMIV ) diagnostic criterion schizophrenia schizoaffective disorder Meets diagnostic criterion marijuana use disorder , determine rating 3 high Drug Use Scale ( Abuse Dependence ) Used marijuana 5 day 3 week prior study entry Taking oral antipsychotic clozapine month prior study entry . ( Patients may take second oral antipsychotic medication , approve Medication Adjustment Group ) If female , willing use effective contraception throughout study Unable take clozapine medical reason , include previous clozapineinduced granulocytopenia , myeloproliferative disorder , white blood cell count less 3500/mm3 , history seizure Currently take clozapine Currently take psychotropic medication treatment substance use ( e.g. , disulfiram , naltrexone , acamprosate , inderol , tegretol , topiramate , pramipexole ) Participated clinical trial investigational drug within 30 day study entry Currently participate psychosocial intervention clinical trial Has medical legal problem may entail jail hospital stay study Has developmental disability would make study participation difficult Currently enrol livein treatment program substance use disorder Pregnant plan become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Clozapine</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Dual Diagnosis</keyword>
	<keyword>Substance Abuse</keyword>
	<keyword>Cannabis Abuse</keyword>
</DOC>